140 related articles for article (PubMed ID: 22103975)
41. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.
Ma D; Fang Q; Wang P; Gao R; Wu W; Lu T; Cao L; Hu X; Wang J
J Biol Chem; 2015 May; 290(20):12558-71. PubMed ID: 25802333
[TBL] [Abstract][Full Text] [Related]
42. Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia.
Xiao Y; Hu HH; Wang HX; Zhu XJ; Zou P; Chen ZC; Zhong ZD; Li WM; You Y
Acta Pharmacol Sin; 2012 Jul; 33(7):979-80. PubMed ID: 22684027
[No Abstract] [Full Text] [Related]
43. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
von Bubnoff N; Veach DR; van der Kuip H; Aulitzky WE; Sänger J; Seipel P; Bornmann WG; Peschel C; Clarkson B; Duyster J
Blood; 2005 Feb; 105(4):1652-9. PubMed ID: 15459011
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
[TBL] [Abstract][Full Text] [Related]
45. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Wu J; Meng F; Lu H; Kong L; Bornmann W; Peng Z; Talpaz M; Donato NJ
Blood; 2008 Apr; 111(7):3821-9. PubMed ID: 18235045
[TBL] [Abstract][Full Text] [Related]
46. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Golemovic M; Verstovsek S; Giles F; Cortes J; Manshouri T; Manley PW; Mestan J; Dugan M; Alland L; Griffin JD; Arlinghaus RB; Sun T; Kantarjian H; Beran M
Clin Cancer Res; 2005 Jul; 11(13):4941-7. PubMed ID: 16000593
[TBL] [Abstract][Full Text] [Related]
47. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
Sausville EA
J Natl Cancer Inst; 1999 Jan; 91(2):102-3. PubMed ID: 9923844
[No Abstract] [Full Text] [Related]
48. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
[TBL] [Abstract][Full Text] [Related]
49. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
O'Hare T; Walters DK; Stoffregen EP; Jia T; Manley PW; Mestan J; Cowan-Jacob SW; Lee FY; Heinrich MC; Deininger MW; Druker BJ
Cancer Res; 2005 Jun; 65(11):4500-5. PubMed ID: 15930265
[TBL] [Abstract][Full Text] [Related]
50. Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
Lamontanara AJ; Gencer EB; Kuzyk O; Hantschel O
Biochim Biophys Acta; 2013 Jul; 1834(7):1449-59. PubMed ID: 23277196
[TBL] [Abstract][Full Text] [Related]
51. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
Chen M; Gallipoli P; DeGeer D; Sloma I; Forrest DL; Chan M; Lai D; Jorgensen H; Ringrose A; Wang HM; Lambie K; Nakamoto H; Saw KM; Turhan A; Arlinghaus R; Paul J; Stobo J; Barnett MJ; Eaves A; Eaves CJ; Holyoake TL; Jiang X
J Natl Cancer Inst; 2013 Mar; 105(6):405-23. PubMed ID: 23446755
[TBL] [Abstract][Full Text] [Related]
52. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Eiring AM; Page BDG; Kraft IL; Mason CC; Vellore NA; Resetca D; Zabriskie MS; Zhang TY; Khorashad JS; Engar AJ; Reynolds KR; Anderson DJ; Senina A; Pomicter AD; Arpin CC; Ahmad S; Heaton WL; Tantravahi SK; Todic A; Moriggl R; Wilson DJ; Baron R; O'Hare T; Gunning PT; Deininger MW
Leukemia; 2015 Mar; 29(3):586-597. PubMed ID: 25134459
[TBL] [Abstract][Full Text] [Related]
53. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
54. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
[TBL] [Abstract][Full Text] [Related]
55. Imatinib resistance: obstacles and opportunities.
Litzow MR
Arch Pathol Lab Med; 2006 May; 130(5):669-79. PubMed ID: 16683885
[TBL] [Abstract][Full Text] [Related]
56. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
57. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
J Natl Cancer Inst; 2000 Oct; 92(20):1641-50. PubMed ID: 11036109
[TBL] [Abstract][Full Text] [Related]
58. What is new in chronic myeloid leukaemia?
Heaney NB; Holyoake TL
Scott Med J; 2007 Feb; 52(1):36-41; quiz 42, 58. PubMed ID: 17373424
[TBL] [Abstract][Full Text] [Related]
59. Nilotinib and imatinib inhibit cytarabine cellular uptake: implications for combination therapy.
Naud JS; Ghani K; de Campos-Lima PO; Caruso M
Leuk Res; 2012 Oct; 36(10):1311-4. PubMed ID: 22796208
[TBL] [Abstract][Full Text] [Related]
60. Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein.
Sausville EA
J Natl Cancer Inst; 2000 Oct; 92(20):1626-7. PubMed ID: 11036101
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]